Heterocyclic antiviral compounds

Details Heterocyclic antiviral compounds Heterocyclic antiviral compounds

2007-01-16

2007-01-16

McKane, Joseph K. (Department: 1626)

Organic compounds -- part of the class 532-570 series

Organic compounds

Nitrogen attached directly or indirectly to the purine ring...

Reexamination Certificate

active

11147851

ABSTRACT:
Chemokine receptor antagonists, in particular, 3,7-diazabicyclo[3.3.0]octane compounds according to formula (I) are antagonists of chemokine CCR5 receptors which are useful for treating or preventing an human immunodeficiency virus (HIV) infection, or treating AIDS or ARC. The invention further provides methods for treating diseases that are allieviated with CCR5 antagonists. The invention includes pharmaceutical compositions and methods of using the compounds for the treatment of these diseases. The invention further includes processes for the preparation of compounds according to formula I.

REFERENCES:
patent: 5686459 (1997-11-01), Diederich et al.
patent: 2004/0053986 (2004-03-01), Bjorsne et al.
patent: 3930266 (1991-03-01), None
patent: 1 122 257 (2005-10-01), None
patent: WO 95/13279 (1995-03-01), None
patent: WO 95/15327 (1995-06-01), None
patent: WO 96/07656 (1996-03-01), None
patent: WO 97/11945 (1997-04-01), None
patent: WO 98/06725 (1998-02-01), None
patent: WO 00/38680 (2000-07-01), None
patent: WO 00/39125 (2000-07-01), None
patent: WO 00/55143 (2000-09-01), None
patent: WO 00/66558 (2000-11-01), None
patent: WO 00/66559 (2000-11-01), None
patent: WO 01/44243 (2001-06-01), None
patent: WO 01/90106 (2001-11-01), None
patent: WO 02/07523 (2002-01-01), None
patent: WO 02/060902 (2002-08-01), None
patent: WO 03/097646 (2003-11-01), None
patent: WO 04/056773 (2004-07-01), None
Abou-Gharbia, M.,Synthesis and Structure-Activity Relationship of Substituted Tetrahydro- and Hexahydro-1, 2-benziosothiazol-3-one, 1,1-Dioxides and Thiadiazinoes: Potential Anxiolytic Agents, J. Med. Chem., 1989, pp. 1024-1033, vol. 32.
Agawal, L.,Chemokine receptors: emerging opportunities for new anti-HIV therapies, Expert Opin. Ther. Targets, 2001, pp. 303-326, vol. 5(3).
Baba, M.,A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity, Proc. Nat. Acad. Sci. USA, 1999, pp. 5698-5703, vol. 96.
De Clerq, E.,Emerging anti-HIV Drugs, Exp. Opin. Emerg. Drugs, 2005, pp. 241-274, vol. 10.
Dorr, P.,Abstr. of the 11thConf. on Retroviruses and Opportunistic Infect, San Francisco, CA, USA, Feb. 10-14, 2003, Abstract, 12.
Dooseop, K..,Discovery of Human CCR5 Antagonists Containing Hydantoins for the Treatment of HIV-1 Infection, Bioorg. Med. Chem. Lett., 2001, pp. 3099-3102, vol. 11.
Dorr, P.,Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity, Antimicrob. Agents Chemother., 2005, pp. 4721-4732, vol. 49(11).
Finke, P.,Antagonists of the Human CCR5 Receptor as Anti-HIV-1 Agents Part 4: Synthesis and Structure-Activity Relationships for 1-[N-(Methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-(4-(N-(alkyl)-N-(benzyloxycarbonyl)amino)piperidin-1-yl)butanes, Bioorg. Med. Chem. Lett. 2001, pp. 2475-2479, vol. 11.
Finke, P.,Antagonists of the Human CCR5 Receptor as anti-HIV-1 agents, Part 2: Structure-Activity Relationships for Substituted 2-Aryl-1-[N(methyl)-N-(phenylsulfonyl)amino]-4-(piperidin-1-yl)butanes, Biorg. Med. Chem. Lett., 2001, pp. 265-270, vol. 11.
Finke, P.,Antagonists of the Human CCR5 Receptor as Anti-HIV-1 Agents. Part 3: a Proposed Pharmacophore Model for 1-[N-(Methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-[4-(substituted)piperidin-1-yl]butances, Bioorg. Med. Chem. Lett., 2001, pp. 2469-2473, vol. 11.
Hale, J.1,3,4-Trisubstituted Pyrrolidine CCR5 Receptor Antagonists. Part 2: Lead Optimization Affording Selective, Orally Bioavailable Compounds with Potent Anti-HIV activity, Bioorg. Med. Chem. Lett., 2001, pp. 2741-2745, vol. 11.
Kazmierski, W.,Recent Progress in Discovery of Small-Molecule CCR5 Chemokine Receptor Ligands as HIV-1 Inhibitors, Biorg. Med. Chem., 2003, pp. 2663-2676, vol. 11.
Macartney, M.,43rdIntersci. Conf. Antimicrob. Agents Chemother., Chicago, IL, USA, Sep. 14-17, 2003, Abstract, H-875;.
Maeda, K.,Novel Low Molecular Weight Spirodiketopiperazine Derivatives Potently Inhibit R5 HIV-1 Infection through Their Antagonistic Effects on CCRD, J. Biol. Chem., 2001, pp. 35194-35200, vol. 276(37).
Maeda, K.,Spirodiketopiperazine-Based CCR5 Inhibitor Which Preserves CC-Chemokine/CCR5 Interactions and Exerts Potent Activity against R5 Human Immunodeficiency Virus Type 1 in Vitro, J. Virol., 2004, pp. 8654-62, vol. 78(16).
Maeda, K.,The current status of, and challenges in, the development of CCR5 inhibitors as therapeutics for HIV-1 infection, Curr. Opin. Pharmacol., 2004, pp. 447-452, vol. 4.
Obst, U.,Synthesis of Novel Nonpeptidic Thrombin Inhibitors, Helv. Chim. Acta., 2000, pp. 855-909, vol. 83.
Palani, A.,Discovery of 4-[(Z)-(4-Bromophenyl)-(ethoxylimino)methyl]-1'-[(2,4-dimethyl-3-pyridinyl)carbonl]-4'-methyl-1,4'-bipiperidine N-Oxide (SCH 351125): An Orally Bioavailable Human CCR5 Antagonist for the Treatment of HIV Infection, J. Med Chem., 2001, pp. 3339-3342, vol. 44(21).
Shiraishi, M.,Discovery of Novel, Potent, and Selective Small-Molecule CCR5 Antagonists as Anti-HIV-1 Agents: Synthesis and Biological Evaluation of Anilide Derivatives with a Quatemary Ammonium Moiety, J. Med. Chem., 2000, pp. 2049-2063, vol. 43(10).
Strizki, J.,SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo, Proc. Nat. Acad. Sci. USA, 2001, pp. 12718-12723, vol. 98.
Tagat, J.,Piperazine-Based CCR5 Antagonists as HIV-1 Inhibitors, Il. Discovery of 1-[2,4-Dimethyl-3-pyridinyl)carbonyl]-4-methyl-4-[3(S)-methyl-4-[1(S)-[4-(trifluromethyl)phenyl]ethyl]-1-piperazinyl]-piperidine N1-Oxide (sch-350634), an Orally Bioavailable, Potent CCR5 Antagonist, J. Med. Chem., 2001, pp. 3343-3346, vol. 44(21).
Watson, C.,The CCR5 Receptor-Based Mechanism of Action of 873140, a Potent Allosteric Noncompetitive HIV Entry Inhibitor, Mol. Pharm., 2005, pp. 1268-1282, vol. 67(4).
Wood, A.,The Discovery of the CCR5 Receptor Antagonist, UK-427,857, A New Agent for the Treatment of HIV Infection and AIDSProg. Med. Chem., 2005, pp. 239-271, vol. 43.

Affiliated with

Also associated with

Rating

Heterocyclic antiviral compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Heterocyclic antiviral compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic antiviral compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3815245